Shamburg News · 8-K filed Nov 10, 2026, 8:40 AM EST
Azitra to Present ATR-COSF and ATR-04 Pipeline Updates at BIO-Europe
AZTR · Azitra, Inc.
- Other event
- Materiality: low
On November 10, 2026, Azitra, Inc. issued a press release, furnished as Exhibit 99.1, announcing that Cofounder and Chief Operating Officer Travis Whitfill will present pipeline updates at the BIO-Europe conference in Cologne, Germany. The presentation reports that ATR-COSF produced a 56% reduction in wrinkles from baseline in an ex vivo human torso skin model and improved elasticity in a second model, and that initial first-in-human results are anticipated by year-end. The release also notes that the ATR-04 Phase 1/2 trial was expanded in October 2026 to include patients with KRAS, MEK inhibitor, and NF1-associated rashes.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001493152-26-050882.
Written from the filing by Shamburg Markets. Figures are as reported by the company.